From Fred Alger Management: Cabaletta是一家临床阶段的生物技术公司,专注于发现和开发自身免疫性疾病的靶向细胞疗法。
该公司的主要候选药物 CABA-201 是一种治疗狼疮和肌炎的细胞疗法,美国食品和药物管理局已接受 CABA-201 的新药申请,为 1/2 期的初步读数...查看全文
产业链观察2022-10-11 19:19
药闻▶2022年10月11日,中国南京和上海,美国宾夕法尼亚州费城和加利福尼亚州圣何塞,——驯鹿生物(“IASO Bio”),一家处于临床阶段、致力于细胞创新药物开发的生物制药公司与$Cabaletta Bio(CABA)$ ,一家致力于针对自身免疫性疾病患者开发和商业化的首个靶向细胞疗法的临床阶段...查看全文
$Cabaletta Bio(CABA)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-21-124712 Act: 34 Size: 62 KB 网页链接
$Cabaletta Bio(CABA)$ DEF 14A Other definitive proxy statements Accession Number: 0001193125-21-124695 Act: 34 Size: 414 KB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001193125-21-106915 Act: 34 Size: 14 MB 网页链接
$Cabaletta Bio(CABA)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-21-082805 Act: 33 Size: 51 KB 网页链接
$Cabaletta Bio(CABA)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001564590-21-013329 Act: 34 Size: 10 MB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-21-082134 Act: 34 Size: 71 KB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-21-009234 Size: 5 KB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-21-009235 Size: 5 KB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-21-009236 Size: 5 KB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-21-009237 Size: 5 KB 网页链接